New approach aims to keep lymphoma at bay after CAR-T treatment
NCT ID NCT07198373
Summary
This study is testing whether taking the drug zanubrutinib as ongoing maintenance therapy can help keep lymphoma from returning after patients receive CAR-T cell therapy. The trial will enroll 40 adults with B-cell lymphoma who have already received or will receive CAR-T treatment. Researchers want to see if this maintenance approach helps patients live longer without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.